Considerations for the use of progestin-only contraceptives

被引:13
作者
Freeman, Sarah [1 ]
Shulman, Lee P. [2 ]
机构
[1] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA
[2] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA
来源
JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS | 2010年 / 22卷 / 02期
关键词
Contraception; implant; injectable; intrauterine; progestin-only; DEPOT-MEDROXYPROGESTERONE ACETATE; BONE-MINERAL DENSITY; IMPLANTABLE CONTRACEPTIVES; SUBCUTANEOUS INJECTION; INTRAUTERINE SYSTEM; ORAL-CONTRACEPTIVES; INJECTABLE CONTRACEPTION; LEUPROLIDE ACETATE; ENDOMETRIAL CANCER; BLEEDING PATTERNS;
D O I
10.1111/j.1745-7599.2009.00473.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: To highlight the characteristics of progestin-only contraceptives (POCs) currently available in the United States, and to explore the potential of these agents as first-line contraceptive options for women seeking health promotion by prevention of an unwanted pregnancy. The progestin-only pills ( Micronor and Ovrette), depot medroxyprogesterone acetate (DMPA) injections (Depo-Provera and depo-subQ provera 104), levonorgestrel intrauterine system (IUS) (Mirena), and etonogestrel implant (Implanon) will be reviewed. The use of levonorgestrel (Plan B) as an emergency contraceptive will also be considered briefly. Data sources: Worldwide medical literature and the prescribing information for the specified products. Conclusions: A number of POCs are currently available for routine birth control in the United States, ranging from the daily progestin-only pill to nondaily contraceptive options such as injectable DMPA, the levonorgestrel-releasing IUS, and the etonogestrel-releasing contraceptive implant. Each of these methods has specific advantages, but also specific drawbacks that can result in discontinuation of treatment if users are not given adequate information about what to expect in terms of side effects. It is critical that clinicians provide adequate and accurate information along with detailed counseling to women who are considering using POCs, as well as providing periodic reinforcement of the information at regular clinic visits for those already using POCs. Implications for practice: Given that a large number of pregnancies are unplanned and create a significant impact on social, economic, and health outcomes, it is important for the clinician to have a vast knowledge of contraceptive options. POCs offer significant choices in contraception. By proactively addressing common concerns (such as potential effects on weight, mood, menstrual bleeding patterns, and bone mineral density), clinicians may improve the likelihood of adherence and continuation with POCs for routine birth control.
引用
收藏
页码:81 / 91
页数:11
相关论文
共 105 条
[1]   Long-acting progestogens [J].
Affandi, B .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2002, 16 (02) :169-179
[2]   RETURN TO FERTILITY AFTER REMOVAL OF A LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE AND NOVA-T [J].
ANDERSSON, K ;
BATAR, I ;
RYBO, G .
CONTRACEPTION, 1992, 46 (06) :575-584
[3]   Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives [J].
Andrist, LC ;
Arias, RD ;
Nucatola, D ;
Kaunitz, AM ;
Musselman, BL ;
Reiter, S ;
Boulanger, J ;
Dominguez, L ;
Emmert, S .
CONTRACEPTION, 2004, 70 (05) :359-363
[4]  
Andrist Linda C, 2004, J Am Acad Nurse Pract, V16, P31
[5]  
[Anonymous], 2005, J FAM PLAN REPROD H, V31, P139
[6]  
[Anonymous], 1992, Contraception, V45, P299
[7]  
[Anonymous], 2005, WHO STAT HORM CONTR
[8]  
[Anonymous], 2004, MED EL CRIT CONTR US, VThird
[9]  
[Anonymous], COCHRANE DATABASE SY
[10]  
[Anonymous], 2006, Obstet Gynecol, DOI [10.1097/00006250-200606000-00055, DOI 10.1097/00006250-200606000-00055.PUBMED:16738183, DOI 10.1097/00006250-200606000-00055]